{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:00:37Z","timestamp":1794254437995,"version":"4.9.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GRK2344"],"award-info":[{"award-number":["GRK2344"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GRK2344"],"award-info":[{"award-number":["GRK2344"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GRK2344"],"award-info":[{"award-number":["GRK2344"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012353","name":"Deutschen Konsortium f\u00fcr Translationale Krebsforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012353","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["FKZ 01ZZ1801B"],"award-info":[{"award-number":["FKZ 01ZZ1801B"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["FKZ 01ZZ1801B"],"award-info":[{"award-number":["FKZ 01ZZ1801B"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Deutsches Krebsforschungszentrum (DKFZ)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Current therapeutic management of advanced melanoma patients largely depends on their BRAF mutation status. However, the vast heterogeneity of the tumors hampers the success of therapies targeting the MAPK\/ERK pathway alone. Dissecting this heterogeneity will contribute to identifying key players in the oncogenic progression to tailor more effective therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We performed a comprehensive molecular and phenotypic characterization of a panel of patient-derived BRAF\n                      <jats:sup>\n                        <jats:italic>V600E<\/jats:italic>\n                      <\/jats:sup>\n                      -positive melanoma cell lines. Transcriptional profiling was used to identify groups of coregulated genes whose expression relates to an increased migratory potential and a higher resistance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A decrease in sensitivity to MAPK\/ERK pathway inhibition with vemurafenib or trametinib corresponded with an increasing quiescence and migratory properties of the cells. This was accompanied by the loss of transcriptional signatures of melanocytic differentiation, and the gain of stem cell features that conferred highly-resistant\/mesenchymal-like cells with increased xenobiotic efflux capacity. Nevertheless, targeting of the implicated ABC transporters did not improve the response to vemurafenib, indicating that incomplete BRAF inhibition due to reduced drug uptake is not a main driver of resistance. Rather, indifference to MAPK\/ERK pathway inhibition arose from the activation of compensatory signaling cascades. The PI3K\/AKT pathway in particular showed a higher activity in mesenchymal-like cells, conferring a lower dependency on MAPK\/ERK signaling and supporting stem-like properties that could be reverted by dual PI3K\/mTOR inhibition with dactolisib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In case of MAPK\/ERK independency, therapeutic focus may be shifted to the PI3K\/AKT pathway to overcome late-stage resistance in melanoma tumors that have acquired a mesenchymal phenotype.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12964-022-00989-y","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T16:31:03Z","timestamp":1669393863000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["PI3K\/AKT signaling allows for MAPK\/ERK pathway independency mediating dedifferentiation-driven treatment resistance in melanoma"],"prefix":"10.1186","volume":"20","author":[{"given":"Eyleen","family":"Corrales","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"Levit-Zerdoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Metzger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Mertes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"M\u00fcnch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Lemke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Kowar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Boerries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,24]]},"reference":[{"key":"989_CR1","unstructured":"American Cancer Society. Melanoma Skin Cancer [Internet]. 2018 [cited 2018 Feb 20]. Available from: https:\/\/www.cancer.org\/cancer\/melanoma-skin-cancer"},{"issue":"7315","key":"989_CR2","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/nature09454","volume":"467","author":"G Bollag","year":"2010","unstructured":"Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010;467(7315):596\u20139.","journal-title":"Nature"},{"issue":"26","key":"989_CR3","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507\u201316.","journal-title":"N Engl J Med"},{"issue":"2","key":"989_CR4","first-page":"96","volume":"38","author":"J McCain","year":"2013","unstructured":"McCain J. The MAPK (ERK) pathway. Pharm Ther. 2013;38(2):96\u2013108.","journal-title":"Pharm Ther"},{"key":"989_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2016.00033","author":"C Wellbrock","year":"2016","unstructured":"Wellbrock C, Arozarena I. The complexity of the ERK\/MAP-Kinase pathway and the treatment of melanoma skin cancer. Front Cell Dev Biol. 2016. https:\/\/doi.org\/10.3389\/fcell.2016.00033.","journal-title":"Front Cell Dev Biol"},{"issue":"7463","key":"989_CR6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415\u201321.","journal-title":"Nature"},{"issue":"6","key":"989_CR7","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.tranon.2017.09.007","volume":"10","author":"TM Grzywa","year":"2017","unstructured":"Grzywa TM, Paskal W, W\u0142odarski PK. Intratumor and intertumor heterogeneity in melanoma. Transl Oncol. 2017;10(6):956\u201375.","journal-title":"Transl Oncol"},{"issue":"4","key":"989_CR8","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1034\/j.1600-0625.2002.110402.x","volume":"11","author":"S Eichm\u00fcller","year":"2002","unstructured":"Eichm\u00fcller S, Usener D, Jochim A, Schadendorf D. mRNA expression of tumor-associated antigens in melanoma tissues and cell lines. Exp Dermatol. 2002;11(4):292\u2013301.","journal-title":"Exp Dermatol"},{"key":"989_CR9","unstructured":"Yan J. som: Self-Organizing Map [Internet]. 2016. Available from: https:\/\/CRAN.R-project.org\/package=som"},{"key":"989_CR10","doi-asserted-by":"crossref","unstructured":"Asan U, Ercan S. An introduction to self-organizing maps. In: 2012. p. 299\u2013319.","DOI":"10.2991\/978-94-91216-77-0_14"},{"issue":"1","key":"989_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.6026\/97320630002005","volume":"2","author":"L Kumar","year":"2007","unstructured":"Kumar L, Futschik M. Mfuzz: a software package for soft clustering of microarray data. Bioinformation. 2007;2(1):5\u20137.","journal-title":"Bioinformation"},{"issue":"5","key":"989_CR12","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284\u20137.","journal-title":"OMICS"},{"issue":"D1","key":"989_CR13","doi-asserted-by":"publisher","first-page":"D380","DOI":"10.1093\/nar\/gkx1013","volume":"46","author":"H Han","year":"2018","unstructured":"Han H, Cho JW, Lee S, Yun A, Kim H, Bae D, et al. TRRUST v2: an expanded reference database of human and mouse transcriptional regulatory interactions. Nucleic Acids Res. 2018;46(D1):D380\u20136.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"989_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14(1):1\u201315.","journal-title":"BMC Bioinformatics"},{"issue":"28","key":"989_CR15","doi-asserted-by":"publisher","first-page":"9709","DOI":"10.1073\/pnas.0803479105","volume":"105","author":"O Mart\u00ednez","year":"2008","unstructured":"Mart\u00ednez O, Reyes-Vald\u00e9s MH. Defining diversity, specialization, and gene specificity in transcriptomes through information theory. Proc Natl Acad Sci. 2008;105(28):9709\u201314.","journal-title":"Proc Natl Acad Sci"},{"key":"989_CR16","doi-asserted-by":"crossref","unstructured":"Meijering E, Dzyubachyk O, Smal I. Methods for cell and particle tracking. In: Conn PM, editor. Methods in Enzymology [Internet]. Academic Press; 2012 [cited 2022 Mar 9]. p. 183\u2013200. (Imaging and Spectroscopic Analysis of Living Cells; vol. 504). Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/B9780123918574000094","DOI":"10.1016\/B978-0-12-391857-4.00009-4"},{"issue":"8","key":"989_CR17","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/gcc.20785","volume":"49","author":"A Gast","year":"2010","unstructured":"Gast A, Scherer D, Chen B, Bloethner S, Melchert S, Sucker A, et al. Somatic alterations in the melanoma genome: a high-resolution array-based comparative genomic hybridization study. Genes Chromosom Cancer. 2010;49(8):733\u201345.","journal-title":"Genes Chromosom Cancer"},{"issue":"4","key":"989_CR18","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/pcmr.12110","volume":"26","author":"KA Tworkoski","year":"2013","unstructured":"Tworkoski KA, Platt JT, Bacchiocchi A, Bosenberg M, Boggon TJ, Stern DF. MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL. Pigment Cell Melanoma Res. 2013;26(4):527\u201341.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"6","key":"989_CR19","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nrm3591","volume":"14","author":"TH Cheung","year":"2013","unstructured":"Cheung TH, Rando TA. Molecular regulation of stem cell quiescence. Nat Rev Mol Cell Biol. 2013;14(6):329\u201340.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"989_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0038280","volume":"7","author":"T Yamada","year":"2012","unstructured":"Yamada T, Park CS, Burns A, Nakada D, Lacorazza HD. The cytosolic protein G0S2 maintains quiescence in hematopoietic stem cells. PLoS ONE. 2012;7(5): e38280.","journal-title":"PLoS ONE"},{"issue":"4","key":"989_CR21","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/j.1600-0749.2006.00322.x","volume":"19","author":"KS Hoek","year":"2006","unstructured":"Hoek KS, Schlegel NC, Brafford P, Sucker A, Ugurel S, Kumar R, et al. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res. 2006;19(4):290\u2013302.","journal-title":"Pigment Cell Res"},{"issue":"1","key":"989_CR22","doi-asserted-by":"publisher","first-page":"6683","DOI":"10.1038\/ncomms7683","volume":"6","author":"A Verfaillie","year":"2015","unstructured":"Verfaillie A, Imrichova H, Atak ZK, Dewaele M, Rambow F, Hulselmans G, et al. Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state. Nat Commun. 2015;6(1):6683.","journal-title":"Nat Commun"},{"issue":"1","key":"989_CR23","doi-asserted-by":"publisher","first-page":"5712","DOI":"10.1038\/ncomms6712","volume":"5","author":"J M\u00fcller","year":"2014","unstructured":"M\u00fcller J, Krijgsman O, Tsoi J, Robert L, Hugo W, Song C, et al. Low MITF\/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat Commun. 2014;5(1):5712.","journal-title":"Nat Commun"},{"key":"989_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.cellimm.2017.10.008","volume":"323","author":"Y Bai","year":"2018","unstructured":"Bai Y, Bai L, Zhou J, Chen H, Zhang L. Sequential delivery of VEGF, FGF-2 and PDGF from the polymeric system enhance HUVECs angiogenesis in vitro and CAM angiogenesis. Cell Immunol. 2018;323:19\u201332.","journal-title":"Cell Immunol"},{"issue":"6","key":"989_CR25","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1002\/stem.1365","volume":"31","author":"PA Campbell","year":"2013","unstructured":"Campbell PA, Rudnicki MA. Oct4 interaction with Hmgb2 regulates Akt signaling and pluripotency. Stem Cells. 2013;31(6):1107\u201320.","journal-title":"Stem Cells"},{"issue":"521","key":"989_CR26","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.canlet.2021.08.026","volume":"28","author":"M Sheta","year":"2021","unstructured":"Sheta M, Hassan G, Afify SM, Monzur S, Kumon K, Abu Quora HA, et al. Chronic exposure to FGF2 converts iPSCs into cancer stem cells with an enhanced integrin\/focal adhesion\/PI3K\/AKT axis. Cancer Lett. 2021;28(521):142\u201354.","journal-title":"Cancer Lett"},{"issue":"3","key":"989_CR27","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.molcel.2019.11.009","volume":"77","author":"MR Webster","year":"2020","unstructured":"Webster MR, Fane ME, Alicea GM, Basu S, Kossenkov AV, Marino GE, et al. Paradoxical role for wild-type p53 in driving therapy resistance in melanoma. Mol Cell. 2020;77(3):633\u201344.","journal-title":"Mol Cell"},{"issue":"5","key":"989_CR28","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S1097-2765(00)00109-X","volume":"6","author":"JB Weitzman","year":"2000","unstructured":"Weitzman JB, Fiette L, Matsuo K, Yaniv M. JunD protects cells from p53-dependent senescence and apoptosis. Mol Cell. 2000;6(5):1109\u201319.","journal-title":"Mol Cell"},{"issue":"24","key":"989_CR29","doi-asserted-by":"publisher","first-page":"6131","DOI":"10.1158\/0008-5472.CAN-21-2078","volume":"81","author":"S Yokoyama","year":"2021","unstructured":"Yokoyama S, Takahashi A, Kikuchi R, Nishibu S, Lo JA, Hejna M, et al. SOX10 regulates melanoma immunogenicity through an IRF4\u2013IRF1 Axis. Can Res. 2021;81(24):6131\u201341.","journal-title":"Can Res"},{"issue":"5","key":"989_CR30","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.ccell.2018.03.017","volume":"33","author":"J Tsoi","year":"2018","unstructured":"Tsoi J, Robert L, Paraiso K, Galvan C, Sheu KM, Lay J, et al. Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress. Cancer Cell. 2018;33(5):890\u2013904.","journal-title":"Cancer Cell"},{"issue":"5","key":"989_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010398","volume":"5","author":"O Mart\u00ednez","year":"2010","unstructured":"Mart\u00ednez O, Reyes-Vald\u00e9s MH, Herrera-Estrella L. Cancer reduces transcriptome specialization. PLOS ONE. 2010;5(5): e10398.","journal-title":"PLOS ONE"},{"issue":"7414","key":"989_CR32","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature11247","volume":"489","author":"ENCODE Project Consortium","year":"2012","unstructured":"ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489(7414):57\u201374.","journal-title":"Nature"},{"issue":"6, Part B","key":"989_CR33","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.ygeno.2014.09.010","volume":"104","author":"KD Haltaufderhyde","year":"2014","unstructured":"Haltaufderhyde KD, Oancea E. Genome-wide transcriptome analysis of human epidermal melanocytes. Genomics. 2014;104(6, Part B):482\u20139.","journal-title":"Genomics"},{"issue":"1","key":"989_CR34","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12964-021-00801-3","volume":"19","author":"E Corrales","year":"2021","unstructured":"Corrales E, Levit-Zerdoun E, Metzger P, Kowar S, Ku M, Brummer T, et al. Dynamic transcriptome analysis reveals signatures of paradoxical effect of vemurafenib on human dermal fibroblasts. Cell Commun Signal. 2021;19(1):123.","journal-title":"Cell Commun Signal"},{"key":"989_CR35","doi-asserted-by":"publisher","first-page":"1740936","DOI":"10.1155\/2016\/1740936","volume":"2016","author":"W Chen","year":"2016","unstructured":"Chen W, Dong J, Haiech J, Kilhoffer MC, Zeniou M. Cancer stem cell quiescence and plasticity as major challenges in cancer therapy. Stem Cells Int. 2016;2016:1740936.","journal-title":"Stem Cells Int"},{"issue":"2","key":"989_CR36","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.stem.2011.01.007","volume":"8","author":"A Golebiewska","year":"2011","unstructured":"Golebiewska A, Brons NHC, Bjerkvig R, Niclou SP. Critical appraisal of the side population assay in stem cell and cancer stem cell research. Cell Stem Cell. 2011;8(2):136\u201347.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"989_CR37","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1186\/1756-0500-7-710","volume":"7","author":"M Michaelis","year":"2014","unstructured":"Michaelis M, Rothweiler F, Nerreter T, van Rikxoort M, Zehner R, Dirks WG, et al. Association between acquired resistance to PLX4032 (vemurafenib) and ATP-binding cassette transporter expression. BMC Res Notes. 2014;7(1):710.","journal-title":"BMC Res Notes"},{"issue":"11","key":"989_CR38","doi-asserted-by":"publisher","first-page":"4519","DOI":"10.1073\/pnas.0900780106","volume":"106","author":"CA Pratilas","year":"2009","unstructured":"Pratilas CA, Taylor BS, Ye Q, Viale A, Sander C, Solit DB, et al. V600EBRAF is associated with disabled feedback inhibition of RAF\u2013MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci USA. 2009;106(11):4519\u201324.","journal-title":"Proc Natl Acad Sci U.S.A."},{"issue":"1","key":"989_CR39","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/ng1054","volume":"33","author":"PM Pollock","year":"2003","unstructured":"Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003;33(1):19\u201320.","journal-title":"Nat Genet"},{"issue":"7","key":"989_CR40","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1093\/carcin\/bgi066","volume":"26","author":"S Bloethner","year":"2005","unstructured":"Bloethner S, Chen B, Hemminki K, M\u00fcller-Berghaus J, Ugurel S, Schadendorf D, et al. Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines. Carcinogenesis. 2005;26(7):1224\u201332.","journal-title":"Carcinogenesis"},{"issue":"23","key":"989_CR41","doi-asserted-by":"publisher","first-page":"4060","DOI":"10.1038\/sj.onc.1207563","volume":"23","author":"S Pavey","year":"2004","unstructured":"Pavey S, Johansson P, Packer L, Taylor J, Stark M, Pollock PM, et al. Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene. 2004;23(23):4060\u20137.","journal-title":"Oncogene"},{"issue":"8","key":"989_CR42","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/s41556-020-0547-3","volume":"22","author":"J Wouters","year":"2020","unstructured":"Wouters J, Kalender-Atak Z, Minnoye L, Spanier KI, De Waegeneer M, Bravo Gonz\u00e1lez-Blas C, et al. Robust gene expression programs underlie recurrent cell states and phenotype switching in melanoma. Nat Cell Biol. 2020;22(8):986\u201398.","journal-title":"Nat Cell Biol"},{"issue":"1","key":"989_CR43","doi-asserted-by":"publisher","first-page":"905","DOI":"10.15252\/msb.20166796","volume":"13","author":"M Fallahi-Sichani","year":"2017","unstructured":"Fallahi-Sichani M, Becker V, Izar B, Baker GJ, Lin JR, Boswell SA, et al. Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state. Mol Syst Biol. 2017;13(1):905.","journal-title":"Mol Syst Biol"},{"issue":"7","key":"989_CR44","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1158\/2159-8290.CD-13-0424","volume":"4","author":"DJ Konieczkowski","year":"2014","unstructured":"Konieczkowski DJ, Johannessen CM, Abudayyeh O, Kim JW, Cooper ZA, Piris A, et al. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discov. 2014;4(7):816\u201327.","journal-title":"Cancer Discov"},{"issue":"8","key":"989_CR45","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1158\/2159-8290.CD-17-1178","volume":"8","author":"A Mehta","year":"2018","unstructured":"Mehta A, Kim YJ, Robert L, Tsoi J, Comin-Anduix B, Berent-Maoz B, et al. Immunotherapy resistance by inflammation-induced dedifferentiation. Cancer Discov. 2018;8(8):935\u201343.","journal-title":"Cancer Discov"},{"issue":"1","key":"989_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-15956-9","volume":"11","author":"Y Su","year":"2020","unstructured":"Su Y, Ko ME, Cheng H, Zhu R, Xue M, Wang J, et al. Multi-omic single-cell snapshots reveal multiple independent trajectories to drug tolerance in a melanoma cell line. Nat Commun. 2020;11(1):1\u201312.","journal-title":"Nat Commun"},{"issue":"2","key":"989_CR47","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/cr.2012.11","volume":"22","author":"A Achilleos","year":"2012","unstructured":"Achilleos A, Trainor PA. Neural crest stem cells: discovery, properties and potential for therapy. Cell Res. 2012;22(2):288\u2013304.","journal-title":"Cell Res"},{"issue":"1","key":"989_CR48","doi-asserted-by":"publisher","first-page":"6","DOI":"10.20517\/cdr.2018.02","volume":"1","author":"AC Jaramillo","year":"2018","unstructured":"Jaramillo AC, Saig FA, Cloos J, Jansen G, Peters GJ. How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance? Cancer Drug Resist. 2018;1(1):6\u201329.","journal-title":"Cancer Drug Resist"},{"key":"989_CR49","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1042\/bse0500209","volume":"50","author":"FJ Sharom","year":"2011","unstructured":"Sharom FJ, Tamaki A, Ierano C, Szakacs G, Robey RW, Bates SE. The controversial role of ABC transporters in clinical oncology. Essays Biochem. 2011;50:209\u201332.","journal-title":"Essays Biochem"},{"issue":"2","key":"989_CR50","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1091\/mbc.3.2.197","volume":"3","author":"Y Funasaka","year":"1992","unstructured":"Funasaka Y, Boulton T, Cobb M, Yarden Y, Fan B, Lyman SD, et al. c-Kit-kinase induces a cascade of protein tyrosine phosphorylation in normal human melanocytes in response to mast cell growth factor and stimulates mitogen-activated protein kinase but is down-regulated in melanomas. MBoC. 1992;3(2):197\u2013209.","journal-title":"MBoC"},{"issue":"2","key":"989_CR51","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1046\/j.1523-1747.1998.00272.x","volume":"111","author":"JM Grichnik","year":"1998","unstructured":"Grichnik JM, Burch JA, Burchette J, Shea CR. The SCF\/KIT pathway plays a critical role in the control of normal human melanocyte homeostasis. J Investig Dermatol. 1998;111(2):233\u20138.","journal-title":"J Investig Dermatol"},{"issue":"48","key":"989_CR52","doi-asserted-by":"publisher","first-page":"20411","DOI":"10.1073\/pnas.0905833106","volume":"106","author":"CM Emery","year":"2009","unstructured":"Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. PNAS. 2009;106(48):20411\u20136.","journal-title":"PNAS"},{"issue":"7377","key":"989_CR53","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nature10662","volume":"480","author":"PI Poulikakos","year":"2011","unstructured":"Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011;480(7377):387\u201390.","journal-title":"Nature"},{"issue":"318","key":"989_CR54","doi-asserted-by":"publisher","first-page":"ra30","DOI":"10.1126\/scisignal.2004815","volume":"7","author":"B Sanchez-Laorden","year":"2014","unstructured":"Sanchez-Laorden B, Viros A, Girotti MR, Pedersen M, Saturno G, Zambon A, et al. BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling. Sci signal. 2014;7(318):ra30\u2013ra30.","journal-title":"Sci signal"},{"key":"989_CR55","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0470","author":"SR Whittaker","year":"2013","unstructured":"Whittaker SR, Theurillat JP, Allen EV, Wagle N, Hsiao J, Cowley GS, et al. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov. 2013. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0470.","journal-title":"Cancer Discov"},{"issue":"17","key":"989_CR56","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.3390\/ijms20174235","volume":"20","author":"S Nymark Aasen","year":"2019","unstructured":"Nymark Aasen S, Parajuli H, Hoang T, Feng Z, Stokke K, Wang J, et al. Effective treatment of metastatic melanoma by combining MAPK and PI3K signaling pathway inhibitors. Int J Mol Sci. 2019;20(17):4235.","journal-title":"Int J Mol Sci"},{"issue":"24","key":"989_CR57","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1038\/s41388-018-0205-4","volume":"37","author":"Q Zuo","year":"2018","unstructured":"Zuo Q, Liu J, Huang L, Qin Y, Hawley T, Seo C, et al. AXL\/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma. Oncogene. 2018;37(24):3275\u201389.","journal-title":"Oncogene"},{"issue":"41","key":"989_CR58","doi-asserted-by":"publisher","first-page":"16158","DOI":"10.1073\/pnas.0702596104","volume":"104","author":"J Zhou","year":"2007","unstructured":"Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang Y, Deng J, et al. Activation of the PTEN\/mTOR\/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci. 2007;104(41):16158\u201363.","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"989_CR59","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.stem.2009.01.007","volume":"4","author":"AM Bleau","year":"2009","unstructured":"Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW, et al. PTEN\/PI3K\/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell. 2009;4(3):226\u201335.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"989_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12964-014-0052-z","volume":"12","author":"P Ostyn","year":"2014","unstructured":"Ostyn P, El Machhour R, Begard S, Kotecki N, Vandomme J, Flamenco P, et al. Transient TNF regulates the self-renewing capacity of stem-like label-retaining cells in sphere and skin equivalent models of melanoma. Cell Commun Signal. 2014;12(1):1\u201313.","journal-title":"Cell Commun Signal"},{"issue":"1","key":"989_CR61","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/exd.12580","volume":"24","author":"NC Schlegel","year":"2015","unstructured":"Schlegel NC, von Planta A, Widmer DS, Dummer R, Christofori G. PI3K signalling is required for a TGF\u03b2-induced epithelial\u2013mesenchymal-like transition (EMT-like) in human melanoma cells. Exp Dermatol. 2015;24(1):22\u20138.","journal-title":"Exp Dermatol"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-022-00989-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-022-00989-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-022-00989-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T19:25:13Z","timestamp":1691781913000},"score":1,"resource":{"primary":{"URL":"https:\/\/biosignaling.biomedcentral.com\/articles\/10.1186\/s12964-022-00989-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,24]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["989"],"URL":"https:\/\/doi.org\/10.1186\/s12964-022-00989-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.07.08.499090","asserted-by":"object"}],"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.21203\/rs.3.rs-3256853\/v1","asserted-by":"subject"}]},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,24]]},"assertion":[{"value":"2 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"187"}}